Promis Neurosciences INC 10-Q quarterly reports

ProMIS Neurosciences Inc. details positive interim clinical trial data for its lead Alzheimer's candidate, PMN310, and a significantly improved cash position following a substantial PIPE financing.

ProMIS Neurosciences Inc. reported its first quarter 2026 financial results, highlighting significant progress in its Alzheimer's drug candidate PMN310 and a substantial increase in cash reserves following a successful private placement.

ProMIS Neurosciences reported a significant net loss in Q3 2025, raising capital through warrant exercises and offerings, but faces substantial doubt about its ability to continue as a going concern.

ProMIS Neurosciences reported increased net losses and negative working capital for Q2 2025, but subsequently secured $21.6 million in gross proceeds to support ongoing operations and clinical trials.

ProMIS Neurosciences reports a net loss of $7.3 million for Q1 2025 and highlights the ongoing Phase 1b clinical trial for PMN310 in Alzheimer's disease.

ProMIS Neurosciences reported its Q3 2024 financial results, highlighting progress in its PMN310 clinical trial and a significant private placement.

ProMIS Neurosciences reported its second quarter 2024 financial results, highlighted by progress in its PMN310 clinical trial and a recent $30.3 million private placement.

ProMIS Neurosciences reported a net loss of $3.6 million for the first quarter of 2024, highlighting ongoing clinical trial progress and financial uncertainties.